CoChat

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds

Open access

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.

Abstract

Novel targets are required to improve the outcomes for patients with colorectal cancers. In this regard, the selective inhibitor of the pro-survival protein BCL2, venetoclax, has proven highly effective in several hematological malignancies. In addition to BCL2, potent and highly selective small molecule inhibitors of its relatives, BCLxL and MCL1, are now available, prompting us to investigate the susceptibility of colorectal cancers to the inhibition of one or more of these pro-survival proteins. While targeting BCLxL, but not BCL2 or MCL1, on its own had some impact, most (15/17) of the immortalized colorectal cancer cell lines studied were efficiently killed by the combined targeting of BCLxL and MCL1. Importantly, these in vitro findings were confirmed in a xenograft model and, interestingly, in all (5/5) patient derived tumor organoids evaluated. Our results lend strong support to the notion that BCLxL and MCL1 are highly promising targets for further evaluation in efforts to improve the treatment of colorectal cancers.

Overview

CoChat Summary

TL;DR

In colorectal cancer models, BCLxL is the primary pro-survival dependency, but dual targeting of BCLxL and MCL1 is required to efficiently kill most cell lines and all patient-derived organoids tested. The findings support further evaluation of BCLxL/MCL1 co-inhibition, while noting potential on-target toxicities.

Key findings

In 17 immortalized human CRC cell lines, BCLxL inhibition alone killed 3/17; MCL1 or BCL2 inhibition alone was ineffective. Combined BCLxL + MCL1 killed 15/17, and adding BCL2 did not improve killing.

  • BH3-mimetic killing was apoptosis-specific: it was fully abrogated in BAX−/−BAK−/− HCT116 cells. RKO showed delayed responses, while LoVo was highly refractory and harbors inactivating BAX mutations.
  • In SW480 xenografts in NSG mice, targeting BCLxL or MCL1 alone modestly suppressed tumor growth, while co-targeting both had a deeper impact.
  • In 5 patient-derived tumor organoids, 3/5 were variably sensitive to BCLxL inhibition alone; all 5 were killed by combined BCLxL/MCL1/BCL2 inhibition. Dependencies: CRC#1 predominantly BCLxL; MCL1 also important in CRC#2–4; BCL2 contributed additionally in CRC#5.

Methods

In vitro: 17 human CRC cell lines treated with selective BH3 mimetics against BCL2 (venetoclax), BCLxL (A1331852), or MCL1 (S64845), alone or in equimolar combinations; viability by CellTiter-Glo after 6 h (some 6–96 h), with IC50 heatmaps and mean IC50s ± SD from three independent experiments where indicated.

  • In vivo: SW480 cells engineered to inducibly express MCL1-selective peptide BIM2A or inert BIM4E control were inoculated subcutaneously into immunodeficient NSG mice; A1331852 25 mg/kg on weekdays for 2 weeks plus doxycycline food; tumor volumes monitored every 2–3 days (three mice/group).
  • Patient-derived organoids: n = 5 treated with 0–1.25 μM BH3 mimetics alone or in equimolar combinations; viability at 24 h, mean IC50s of two independent experiments; rapid apoptosis assessed by propidium iodide staining and imaging.

Limitations

Stated: co-targeting BCLxL and/or MCL1 may be challenging because of on-target toxicities; the authors suggest antibody–drug conjugates to restrict action to tumor cells and call for further laboratory studies.

  • Evident from the text: small sample sizes (17 cell lines, 5 organoids, 3 mice per xenograft group), short-term in vitro viability assays, and no clinical validation; organoid heterogeneity and BAX-mutant LoVo resistance may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41419-020-02815-0

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Colorectal cancer cells are highly susceptible to the dual inhibition of BCLxL and MCL1. a In vitro sensitivity of a panel of colorectal cancer cell lines to the BH3-mimetic drugs. Seventeen CRC lines were treated with 0–10 μM of BH3 mimetics targeting BCLxL, MCL1, and BCL2, alone or in equimolar combinations (1:1 or 1:1:1). Cell viability was determined after 6 h. A discrete heatmap representation of the mean IC50s is shown; red represents potent killing (IC50 < 0.5 μM), whereas blue indicates refractoriness (IC50 > 5 μM). See Supplementary Table 1 for detailed information of the cell lines used. b Killing caused by the combined action of inhibitors targeting BCLxL, MCL1, and BCL2 is mediated by BAX and BAK. The viability of parental HCT 116 cells or a BAX−/−BAK−/− HCT 116 sub-clone was determined 48 h after the combined inhibition of BCLxL, MCL1, and BCL2. c LoVo cells are highly refractory to apoptosis induction. Sensitivity (mean IC50s ± SD) of RKO or LoVo cells treated with the indicated combinations of BH3 mimetics for 6–96 h is shown. d Expression of the MCL1-selective peptide10, BIM2A, enhances the in vivo suppression of tumor growth by the BCLxL inhibitor. The SW480 cells engineered to inducibly express BIM2A or BIM4E (inert control) were inoculated subcutaneously into immunodeficient NSG (NOD SCID IL-2Rγ−/−) mice and treatment commenced 1 week later with 25 mg/kg of the BCLxL inhibitor A1331852 on weekdays for 2 weeks together with doxycycline-containing food to induce expression of BIM2A or BIM4E. Tumor sizes were monitored every 2–3 days and the data shown represent the mean tumor volumes ± SD of three mice in each group. e Sensitivity of patient-derived tumor organoids to the BH3 mimetics. Patient-derived tumor organoids (n = 5) were treated with 0–1.25 μM of the indicated BH3-mimetic, alone, or in equimolar combinations (1:1 or 1:1:1). Cell viability was determined 24 h later and the mean IC50s of two independent experiments are shown. The relative dependency of each organoid on BCLxL, MCL1, and/or BCL2 is inferred. f Rapid induction of apoptosis by BH3-mimetic treatment. The viability of organoid #5 treated with different BH3 mimetics (see e) was determined by PI (red) staining and imaged at indicated time points (see Supplementary Video 1). Scale bar = 100 µm. Cell viability in a–c, e was determined using CellTiter-Glo assays; data in b, c represent the means ± SD from three independent experiments. See Methods in Supplementary Material for experimental details.
Fig. 1 Colorectal cancer cells are highly susceptible to the dual inhibition of BCLxL and MCL1. a In vitro sensitivity of a panel of colorectal cancer cell lines to the BH3-mimetic drugs. Seventeen CRC lines were treated with 0–10 μM of BH3 mimetics targeting BCLxL, MCL1, and BCL2, alone or in equimolar combinations (1:1 or 1:1:1). Cell viability was determined after 6 h. A discrete heatmap representation of the mean IC50s is shown; red represents potent killing (IC50 < 0.5 μM), whereas blue indicates refractoriness (IC50 > 5 μM). See Supplementary Table 1 for detailed information of the cell lines used. b Killing caused by the combined action of inhibitors targeting BCLxL, MCL1, and BCL2 is mediated by BAX and BAK. The viability of parental HCT 116 cells or a BAX−/−BAK−/− HCT 116 sub-clone was determined 48 h after the combined inhibition of BCLxL, MCL1, and BCL2. c LoVo cells are highly refractory to apoptosis induction. Sensitivity (mean IC50s ± SD) of RKO or LoVo cells treated with the indicated combinations of BH3 mimetics for 6–96 h is shown. d Expression of the MCL1-selective peptide10, BIM2A, enhances the in vivo suppression of tumor growth by the BCLxL inhibitor. The SW480 cells engineered to inducibly express BIM2A or BIM4E (inert control) were inoculated subcutaneously into immunodeficient NSG (NOD SCID IL-2Rγ−/−) mice and treatment commenced 1 week later with 25 mg/kg of the BCLxL inhibitor A1331852 on weekdays for 2 weeks together with doxycycline-containing food to induce expression of BIM2A or BIM4E. Tumor sizes were monitored every 2–3 days and the data shown represent the mean tumor volumes ± SD of three mice in each group. e Sensitivity of patient-derived tumor organoids to the BH3 mimetics. Patient-derived tumor organoids (n = 5) were treated with 0–1.25 μM of the indicated BH3-mimetic, alone, or in equimolar combinations (1:1 or 1:1:1). Cell viability was determined 24 h later and the mean IC50s of two independent experiments are shown. The relative dependency of each organoid on BCLxL, MCL1, and/or BCL2 is inferred. f Rapid induction of apoptosis by BH3-mimetic treatment. The viability of organoid #5 treated with different BH3 mimetics (see e) was determined by PI (red) staining and imaged at indicated time points (see Supplementary Video 1). Scale bar = 100 µm. Cell viability in a–c, e was determined using CellTiter-Glo assays; data in b, c represent the means ± SD from three independent experiments. See Methods in Supplementary Material for experimental details.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 3 Not checked · 16 Own results and interpretations

7 more claims

Create a free account to see all 19 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 4
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Citations

Cites

Show all 11 references

Cited by

See all 19

Metadata

Authors
Luo, M.-J., Palmieri, M., Riffkin, C. D., Sakthianandeswaren, A., Djajawi, T. M., Hirokawa, Y., Shuttleworth, V., Segal, D. H., White, C. A., Nhu, D., Lessene, G., Lee, M., Gibbs, P., Huang, D. C. S., Sieber, O. M., & Gong, J.-N.
Affiliations
  • The University of Melbourne (AU)
  • Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author
  • Huang, David C. S.
  • Sieber, Oliver M.
Venue
Cell Death & Disease
Published
2020-09-10
Volume
11
Issue
9
Pages
735-735
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3084257764
Cited by
19
References
11
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2023: 1 · 2022: 4 · 2021: 4
FWCI
0.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
China Scholarship Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
colorectal cancer, BH3 mimetics, Bcl-xL, Mcl-1, Bcl-2, venetoclax, pro-survival proteins, colorectal cancer cell lines, xenograft models, patient-derived tumor organoids, apoptosis
MeSH terms
Animals, Disease Susceptibility, Humans, Peptide Fragments, Proto-Oncogene Proteins, Colorectal Neoplasms, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. https://app.cochat.ai/papers/10.1038/s41419-020-02815-0
The paper
Luo, M.-J., Palmieri, M., Riffkin, C. D., Sakthianandeswaren, A., Djajawi, T. M., Hirokawa, Y., Shuttleworth, V., Segal, D. H., White, C. A., Nhu, D., Lessene, G., Lee, M., Gibbs, P., Huang, D. C. S., Sieber, O. M., & Gong, J.-N. (2020). Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell Death & Disease. https://doi.org/10.1038/s41419-020-02815-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.